Replies to post #2109 on GTC Biotherapeutics (fka GTCB)

[floblu14]

>3: What do you think will/would have the largest positive impact on GTCB’s success.
A) Approval of AT for DIC in Sepsis
B) Approval of AT by US FDA
C) Multiple manufacturing agreements
D) The LFB collaboration agreement
E) The LEO collaboration agreement
F) Limit share dilution<

Would it be permissable to have 2 answers for this one in descending order?

Also, my 6 a.m. mind came up with this enigmatic question for number 4 -
If Dr. Cox were to leave, who would succeed him??

1. Sandra Nusinoff Lehrman
2. Henri
3. Sweetheart
4. Weird Al
5. Harry Meade and/or Tom Newberry
6. Spice is Nice and/or Borat
7. Your pick --

LOL

[dewophile]

re DIC/sepsis
I read the papers just have nothing really to add. We shoudl count ourselves lucky the data cited by waynebio exists to guide the forthcoming trial design. what leo/gtcb should do differently seems clear:

1. limit enrollment to just the DIC subgroup of sepsis pts
2. limit enrollment to patients with high risk (but not highest risk) of mortality
3. allow no concomitant heparin therapy

DIC/sepsis remains a high risk-high reward indication, but the above design (perhaps I missed something so please feel free to edit) should stack the deck as much in favor of success as possible..I think